| Literature DB >> 31083383 |
Rasha M Sareyeldin1,2, Ishita Gupta3,4, Israa Al-Hashimi5,6, Hamda A Al-Thawadi7, Halema F Al Farsi8, Semir Vranic9, Ala-Eddin Al Moustafa10,11.
Abstract
Breast cancer is the second most common cause of cancer-related deaths among women worldwide. It is a heterogeneous disease with four major molecular subtypes. One of the subtypes, human epidermal growth factor receptor 2 (HER2)-enriched (HER2-positive) is characterized by the absence of estrogen and progesterone receptors and overexpression of HER2 receptor, and accounts for 15-20% of all breast cancers. Despite the anti-HER2 and cytotoxic chemotherapy, HER2 subtype is an aggressive disease with significant mortality. Recent advances in molecular biology techniques, including gene expression profiling, proteomics, and microRNA analysis, have been extensively used to explore the underlying mechanisms behind human breast carcinogenesis and metastasis including HER2-positive breast cancer, paving the way for developing new targeted therapies. This review focuses on recent advances on gene expression and miRNA status in HER2-positive breast cancer.Entities:
Keywords: HER2-positive breast cancer; biomarkers; breast cancer; gene expression profiling; miRNAs; microarray
Year: 2019 PMID: 31083383 PMCID: PMC6562440 DOI: 10.3390/cancers11050646
Source DB: PubMed Journal: Cancers (Basel) ISSN: 2072-6694 Impact factor: 6.639